These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 32251995)

  • 1. A comparative study of peptide-based imaging agents [
    Zhang-Yin J; Provost C; Cancel-Tassin G; Rusu T; Penent M; Radulescu C; Comperat E; Cussenot O; Montravers F; Renard-Penna R; Talbot JN; Prignon A
    Nucl Med Biol; 2020; 84-85():88-95. PubMed ID: 32251995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
    Schroeder RP; van Weerden WM; Krenning EP; Bangma CH; Berndsen S; Grievink-de Ligt CH; Groen HC; Reneman S; de Blois E; Breeman WA; de Jong M
    Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Wu W; Yu F; Zhang P; Bu T; Fu J; Ai S; You Q; Shi L; Shao G; Wang F; Hodolic M; Guo H
    J Nucl Med; 2022 Sep; 63(9):1394-1400. PubMed ID: 35177423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
    Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
    Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [
    Kálmán-Szabó I; Szabó JP; Arató V; Dénes N; Opposits G; Jószai I; Kertész I; Képes Z; Fekete A; Szikra D; Hajdu I; Trencsényi G
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative PET imaging study of
    Ferguson S; Wuest M; Richter S; Bergman C; Dufour J; Krys D; Simone J; Jans HS; Riauka T; Wuest F
    Nucl Med Biol; 2020; 90-91():74-83. PubMed ID: 33189947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
    Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
    Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
    Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR
    Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
    Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
    Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use.
    He T; Wang M; Wang H; Tan H; Tang Y; Smith E; Wu Z; Liao W; Hu S; Li Z
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2199-2207. PubMed ID: 31264168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiosynthesis and biological evaluation of 18F-labeled bispecific heterodimer targeted dual gastrin-releasing peptide receptor and prostate-specific membrane antigen for prostate cancer imaging.
    Ye S; Li H; Hu K; Li L; Zhong J; Yan Q; Wang Q
    Nucl Med Commun; 2022 Mar; 43(3):323-331. PubMed ID: 34919064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer.
    Liu Y; Hu X; Liu H; Bu L; Ma X; Cheng K; Li J; Tian M; Zhang H; Cheng Z
    J Nucl Med; 2013 Dec; 54(12):2132-8. PubMed ID: 24198391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Zechmann CM; Malcher A; Eder M; Eisenhut M; Linhart HG; Holland-Letz T; Hadaschik BA; Giesel FL; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):11-20. PubMed ID: 24072344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer.
    Escudero-Castellanos A; Ocampo-García B; Ferro-Flores G; Santos-Cuevas C; Morales-Ávila E; Luna-Gutiérrez M; Isaac-Olivé K
    Nucl Med Commun; 2019 Mar; 40(3):278-286. PubMed ID: 30763290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties.
    Hou H; Pan Y; Wang Y; Ma Y; Niu X; Sun S; Hou G; Tao W; Gao F
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2819-2832. PubMed ID: 38683349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
    Liu Z; Yan Y; Liu S; Wang F; Chen X
    Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation and Pilot Clinical Study of Al
    Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
    J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.